$NRXP

2 theses

bullish 100%neutral 0%bearish 0%

Avg return (3m)

—

Win rate (3m)

— (0 resolved)

1d 3d 1w 1m 3m 6m 1y

Past performance does not predict future results. Informational only, not investment advice.

Recent theses

Prices as of Sep 4, 4:30 PM ET

$NRXPr/pennystocksDDbullish

u/stockratic · 4d ago2 prior · awaiting results

NRx Pharmaceuticals (NRXP) - Two September Catalysts Upon Us

NRx Pharmaceuticals has two major catalysts expected by end-2026: ANDA approval for preservative-free IV ketamine (anytime through Sep 2026) and NDA submission for NRX-100 (psychiatric indication). The company has exclusive market access, domestic supply, and 1M vial/month production capacity. Analyst price targets range $25-$45, with near-term price support of $10-12 on ANDA approval alone.

At post $3.44Now $3.49+1.4% since postedas of Sep 4, 4:30 PM ET

original post →

$NRXPr/pennystocksDDbullish

u/stockratic · 15d ago2 prior · awaiting results

NRx Pharmaceuticals (NRXP) - Awaiting ANDA (generic drug) approval for no-preservative Intravenous (IV) ketamine for analgesia (pain control) and anesthesia ... which will happen in the near term.

NRx Pharmaceuticals is positioned for near-term FDA approval of KETAFREE (preservative-free ketamine), addressing critical supply chain and safety issues while solving strategic FDA goals. The company has resolved the only outstanding FDA concern (luer lock vial attestation) and has significant pre-launch commercialization momentum, with share price expected to respond positively to ANDA approval and subsequent NDA filings.

At post $3.56Now $3.49-2.0% since postedas of Sep 4, 4:30 PM ET

1d—

3d-3.1%

1w-0.3%

1m—

3m—

6m—

1y—

original post →

End of results.